Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13024943 | 0.90 | HTR1A (0.82) | HTR1AMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL13024942 | 0.86 | MEN1 (1.00) | HTR1AMEN1KMT2AMAPTHTR2A | |
| SCHEMBL8080161 | 0.82 | HTR1A (0.58) | HTR1AMEN1KMT2A | |
| SCHEMBL8077221 | 0.81 | HTR1A (0.65) | HTR1AMEN1KMT2AMAPTHTR2A | |
| SCHEMBL12123949 | 0.80 | HTR1A (0.66) | HTR1AMEN1KMT2A | |
| SCHEMBL13024951 | 0.79 | HTR1A (0.67) | HTR1AMEN1KMT2A | |
| SCHEMBL13025081 | 0.79 | MAPT (0.60) | HTR1AMEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL13066673 | 0.79 | MAPT (0.60) | HTR1AMEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL13066306 | 0.79 | MAPT (0.60) | HTR1AMEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL13025083 | 0.79 | MAPT (0.60) | HTR1AMEN1KMT2ASLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286164-A1 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 2010-11-11 | — | — | US | claimed |
| WO-2009051661-A2 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20100286164-A1 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286164-A1 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286164-A1 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009051661-A2 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286164-A1 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF | BACE1, BACE2, APP | HTR1A 2118/4885MEN1 4520/4885KMT2A 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.